TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Canaccord Genuity Group

Analysts at Canaccord Genuity Group assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) in a report released on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 67.60% from the company’s […]

Related Keywords

,Canaccord Genuity Group ,Nasdaq ,Exchange Commission ,Trisalus Life Sciences Company Profile ,Analysts At Canaccord Genuity Group ,Trisalus Life Sciences Stock Performance ,News Ratings For Trisalus Life Sciences Daily ,Trisalus Life Sciences Inc ,Hc Advisors ,Trisalus Life Sciences ,Get Free Report ,Genuity Group ,Salus Life Sciences ,Free Report ,Pressure Enabled Drug Delivery ,Pancreatic Retrograde Venous Infusion ,Trisalus Life Sciences Daily ,